[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![$esaiy Graphic](https://lunarcrush.com/gi/w:26/t:$esaiy.png) $esaiy

Crypto markets are experiencing volatility. Positive sentiment is driving some gains.

### About $esaiy
A cryptocurrency.  

### Insights [#](/topic/$esaiy/insights)
- $esaiy engagements is up XXXXX% from the previous week.

### Engagements: X [#](/topic/$esaiy/interactions)
---
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/t:$esaiy/c:line/m:interactions/iv:1d.svg)  
[Engagements 24-Hour Time-Series Raw Data](/topic/$esaiy/time-series/interactions.tsv)  
**Current Value**: X  
**Daily Average**: XXX  
**1 Week**: XXX +35%  
**1 Month**: XXXXX -XX%  
**1-Year High**: XXXXX on 2025-05-15  
**1-Year Low**: X on 2025-06-08  

| Social Network | X |
| -------------- | - |
| Engagements    | X |
  

  
  
### Mentions: X [#](/topic/$esaiy/posts_active)
---
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/t:$esaiy/c:line/m:posts_active/iv:1d.svg)  
[Mentions 24-Hour Time-Series Raw Data](/topic/$esaiy/time-series/posts_active.tsv)  
**Current Value**: X  
**Daily Average**: X  
**1 Month**: X -XX%  
**1-Year High**: XX on 2025-09-23  
**1-Year Low**: X on 2025-05-03  

| Social Network | X |
| -------------- | - |
| Mentions       | X |
  

  
  
### Creators: X [#](/topic/$esaiy/contributors_active)
---
![Creators Line Chart](https://lunarcrush.com/gi/w:600/t:$esaiy/c:line/m:contributors_active/iv:1d.svg)  
[Creators 24-Hour Time-Series Raw Data](/topic/$esaiy/time-series/contributors_active.tsv)  
X unique social accounts have posts mentioning $esaiy in the last XX hours which is down XX% from X in the previous XX hours
**Daily Average**: X  
**1 Month**: X -XX%  
**1-Year High**: X on 2025-09-09  
**1-Year Low**: X on 2025-05-02  

The most influential creators that mention $esaiy in the last XX hours

| Creator                                          | Rank | Followers | Posts | Engagements |
| -------                                          | ---- | --------- | ----- | ----------- |
| [@MarcJacksonLA](/creator/twitter/MarcJacksonLA) | X    | XXXXX     | X     | XX          |

[View More](/list/creators/$esaiy/100)

**Top assets mentioned**
In the posts about $esaiy in the last XX hours

[Biogen Inc (BIIB)](/topic/biogen-inc)
[Biogen Inc (BIIB)](/topic/$biib)
[Eli Lilly and Company (LLY)](/topic/eli-lilly)
[Eli Lilly and Company (LLY)](/topic/$lly)

**Top topics mentioned**
In the posts about $esaiy in the last XX hours

[$bioa](/topic/$bioa), [$4523t](/topic/$4523t), [biogen inc](/topic/biogen-inc), [stocks healthcare](/topic/stocks-healthcare), [china](/topic/china), [united states](/topic/united-states), [breaking news](/topic/breaking-news), [$biib](/topic/$biib), [$esalf](/topic/$esalf), [$rhhby](/topic/$rhhby), [eli lilly](/topic/eli-lilly), [$lly](/topic/$lly)

### Top Social Posts [#](/topic/$esaiy/posts)
---
Top posts by engagements in the last XX hours

*Showing only X posts for non-authenticated requests. Use your API key in requests for full results.*

"$RHHBY $LLY $BIIB $ESAIY Roche Lilly Win First FDA Nod for Alzheimers Blood Test for Primary Care Use"  
[X Link](https://x.com/MarcJacksonLA/status/1978098981080072615) [@MarcJacksonLA](/creator/x/MarcJacksonLA) 2025-10-14T14:02Z 7574 followers, XXX engagements


"👇🏼👇🏼👇🏼👇🏼👇🏼👇🏼👇🏼👇🏼👇🏼👇🏼👇🏼👇🏼👇🏼 $BIOA $ESAIY $ESALF $BIIB @bioarcticab @eisaiusneuro @biogen #Bioarctic #AlzheimersDisease #Leqembi #lecanemab #ParkinsonsDisease #exidavnemab #ALS"  
[X Link](https://x.com/larsen210/status/1975810141493534807) [@larsen210](/creator/x/larsen210) 2025-10-08T06:27Z XXX followers, XX engagements


"$BIOA $ESAIY Leqembi Iqlik (lecanemab-irmb) maintenance treatment launched in the United States BioArctic partner Eisai launched Leqembi Iqlik (lecanemab-irmb) subcutaneous autoinjector in the U.S. on October X 2025 as a maintenance option for early Alzheimers disease (MCI or mild dementia) after an initial 18-month IV induction. After XX months of XX mg/kg IV every two weeks patients may continue IV every four weeks or switch to a weekly XXX mg at-home subcutaneous injection. The company also launched a Leqembi Companion program with nurse education financial/insurance support an injection"  
[X Link](https://x.com/MarcJacksonLA/status/1975332616623825261) [@MarcJacksonLA](/creator/x/MarcJacksonLA) 2025-10-06T22:49Z 7577 followers, XXX engagements


"$BIOA $ESAIY Leqembi approved for IV maintenance treatment in China BioArctic announced that its partner Eisai has received approval from China's NMPA for Leqembi's (lecanemab) IV maintenance treatment in early Alzheimer's disease. The new approval allows for a maintenance dosing regimen of XX mg/kg once every four weeks after an 18-month initiation phase of bi-weekly dosing. Leqembi initially approved in China in January 2024 is notable as the only approved therapy targeting both amyloid plaque and protofibrils in Alzheimer's disease treatment. The drug was developed through a collaboration"  
[X Link](https://x.com/MarcJacksonLA/status/1972551114496393485) [@MarcJacksonLA](/creator/x/MarcJacksonLA) 2025-09-29T06:36Z 7577 followers, XXX engagements